<DOC>
	<DOCNO>NCT01858961</DOCNO>
	<brief_summary>The aim trial evaluate efficacy safety treatment 600 mg BID BI 207127 combination 120 mg QD Faldaprevir RBV compare Telaprevir-based regimen along PegIFN RBV chronically infect HCV GT1 treatment naïve patient , include patient compensated cirrhosis .</brief_summary>
	<brief_title>Open Label Trial Compare BI 207127 Telaprevir HCV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic HCV , diagnose HCV RNA = 1,000 IU/mL screen addition least one following : 1. positive antiHCV antibody detect HCV RNA least 6 month prior screen , OR 2. liver biopsy indicate chronic HCV infection , OR 3. history elevate ALT level least 6 month prior screen . 2 . HCV infection subGT1b confirm genotypic test screening . 3 . Treatment naïve define : 1. prior treatment interferon , pegylated interferon , /or ribavirin 2. prior treatment least one dose license investigational antiviral agent acute chronic hepatitis C infection . 4 . Availability liver biopsy within three year fibroscan within 6 month prior randomisation . Note : patient liver biopsy ( fibroscan ) due contraindication procedure exclude reason . The decision inclusion patient discuss CML . Patients liver biopsy perform 3 year ( fibroscan perform 6 month ) prior randomisation , demonstrate cirrhosis need repeat liver biopsy fibroscan . 5 . Age 18 70 year ( inclusive ) . 6 . Female patient 1. documented hysterectomy , 2. ovary remove , 3. document tubal ligation , 4. postmenopausal last menstrual period least 12 month prior screen , 5. childbearing potential negative serum pregnancy test screen Day 1 ( Visit 2 ) , agree use two nonhormonal method birth control date screen 7 month last dose ribavirin . They must breastfeed time date screen 7 month last dose ribavirin . Accepted method contraception females trial diaphragm spermicide substance , intrauterine device , cervical cap condom . Note : Systemic hormonal contraceptive may effective woman take BI 207127/FDV combination therapy accept method contraception study . OR : Male patient 1. document sterile , 2. consistently correctly use condom female partner ( childbearing potential ) agree use one appropriate medically accept method birth control date screen 7 month last dose ribavirin , 3. without pregnant female partner . It responsibility male patient ensure partner ( partner ) pregnant prior enrolment study become pregnant treatment followup phase . Female partner childbearing potential must perform monthly pregnancy test date screen 7 month last dose ribavirin ( test provide Sponsor ) . 7 . Signed informed consent form prior trial participation . Exclusion criterion : 1 . HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) , HCV subGT1a GT1 undefined , diagnose screen genotypic test . 2 . Liver disease due cause chronic HCV infection may include limited hemochromatosis , Wilson 's disease , autoimmune liver disease . 3 . HIV infection . 4 . Hepatitis B virus ( HBV ) infection base presence Hepatitis B surface antigen . 5 . Evidence decompensated liver disease history decompensated liver disease , define history ascites , hepatic encephalopathy , bleed esophageal varix evidence previous decompensation and/or laboratory result ( International Normalised Ratio , albumin , bilirubin ) indicate ChildPughTurcotte score &gt; 6 point ( i.e . CPTB C ) 6 . Confirmed suspect active malignancy history malignancy within last 5 year ( exception appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix ) . 7 . Patients ongoing historical photosensitivity recurrent rash . 8 . History illicit drug use ( cannabis ) chronic alcohol abuse within 12 month prior randomization , opinion Investigator . 9 . Body mass index &lt; 18 &gt; 35 kg/m2 . 10 . Usage investigational drug within 28 day prior randomisation , plan usage investigational drug course current study . 11 . Known hypersensitivity ingredient study drug . 12 . A condition insufficiently diagnose , treat clinically unstable opinion Investigator may put patient risk participation study , influence result study , limit patient 's ability participate study . 13 . Alpha fetoprotein value &gt; 100ng/mL screening ; &gt; 20ng/mL = 100ng/mL , patient include evidence liver cancer appropriate imaging study within 6 month prior randomisation . 14 . A history severe preexist cardiac disease , include unstable uncontrolled cardiac disease ( e.g . congestive heart failure , myocardial infarction , unstable angina arrhythmic disorder ) current within previous 12 month randomisation . Clinically significant Electrocardiogram ( ECG ) abnormality . A history congenital QT prolongation , family history congenital QT prolongation sudden death . 15 . Received silymarin ( milk thistle ) glycyrrhizin Shosaikoto ( SST ) within 28 day prior randomisation medication list restricted medication list provide ISF within 28 day prior randomisation , exception parenteral analgesic use liver biopsy procedure . 16 . Preexisting psychiatric condition could interfere subject 's participation completion study include limit severe depression hospitalization depression , suicidal ideation attempt suicide , schizophrenia , bipolar illness , severe anxiety personality disorder , history craniocerebral trauma active seizure disorder require medication , period disability impairment due psychiatric disease current within previous 3 year randomisation . 17 . Abnormal thyroid function control effectively medication . 18 . Active autoimmunemediated disease ( e.g. , Crohn 's disease , ulcerative colitis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis ) . 19 . Requirement chronic systemic corticosteroid ( inhale nasally administer pulmonary steroid allow ) . 20 . History evidence severe retinopathy clinically significant ophthalmological disorder due diabetes mellitus hypertension ( limited condition ) . Plus exclusion criterion relate Peg interferon , ribavirin Telaprevir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>